The USFDA inspected the facility from 6th to 12th Februrary 2023.
The US Food Drug and Administration (USFDA) conducted inspection at FDC's manufacturing facility at B-8, MIDC Industrial Area, Waluj, Aurangabad, Maharashtra.The audit was carried out for the sterile ophthalmic products being marketed in the US. The audit concluded with "No observations" (Zero 483s).
FDC is principally engaged in the business of Pharmaceuticals. The company's consolidated net profit rose 14.2% to Rs 40.75 crore on 19.8% jump in net sales to Rs 409.30 crore in Q3 FY23 over Q3 FY22.
The scrip rose 0.87% to Rs 267.15 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
